Nelson N. Stone, MD, presented “3DBiopsy™ Transperineal Mapping Biopsy” during the 23rd Annual Southwest Prostate Cancer Update on April 12, 2018 in Scottsdale, Arizona

How to cite: Stone, Nelson N. “Incorporating New PET Imaging and Theranostic Approaches into Prostate Cancer Practice ” April 12, 2018. Accessed [date today]. https://grandroundsinurology.com/3dbiopsy-transperineal-mapping-biopsy/

3DBiopsy™ Transperineal Mapping Biopsy – Summary:

Nelson N. Stone, MD, Founder and CEO/President of 3DBiopsy™, discusses how his comprehensive system aides in accurately identifying Gleason scores and guiding focal therapy. He and 3DBiopsy™ co-founders, E. David Crawford, MD, and M. Scott Lucia, MD, perform a demonstration as an illustration of the system’s needle, actuator, pathology carrier, and 3D mapping software.

3DBiopsy™ Needle and Actuator

Dr. Stone presents the 3DBiopsy™ adjustable needle with a rigged core bed and a four-point trocar tip, allowing for preserved specimen length as well as reduced needle deflection when firing into tissue. Also, a dial on the side of the actuator allows clinicians to set the intended length of penetration into the gland to any measurement between 20 and 60 millimeters.

Integrated Pathology System Specimen Carrier

Next, Dr. Lucia demonstrates transferring a 4.2 centimeter specimen from a sample prostate to the 3DBiopsy™ Integrated Pathology System (IPS). After gathering a specimen with the needle, he rolls the core bed against the IPS tissues. While the standard method of removing material from the core bed with forceps or a swab causes significant fragmentation, this specimen retained its shape, position, and a length of 4.1 centimeters upon transferal.

Additionally, the IPS lends itself to easy orientation identification, even when splitting the specimen in order to store it in a 3 centimeter processing cassette.

3D Mapping Software

Presently, 3DBiopsy™’s mapping software is under development. The software integrates with both ultrasound and MRI systems to create a “Virtual Prostate” in the operating room. This allows clinicians to plan the length, position, and orientation of sample sites. Furthermore, the software factors in patient information like age, race, prior biopsy, and Gleason scores to create an individualized model.